Background: The imaging of biomarkers for characterization of dopaminergic impairment in
Parkinson's disease (PD) is useful for diagnosis, patient stratification, and assessment of …

Several lines of evidence are indicative of a role for immune activation in the
pathophysiology of schizophrenia. Nevertheless, studies using positron emission …

Objective Surgery launches a systemic inflammatory reaction that reaches the brain and
associates with immune activation and cognitive decline. Although preclinical studies have …

BACKGROUND. Recombinant human PDGF-BB (rhPDGF-BB) reduces Parkinsonian
symptoms and increases dopamine transporter (DAT) binding in several animal models of …

Selective serotonin reuptake inhibitors (SSRIs) are widely prescribed for treatment of
psychiatric disorders. The exact mechanism underlying the clinical effects of SSRIs remains …

Preliminary studies have suggested that γ-aminobutyric acid type A (GABAA) receptors, and
potentially the GABAA α5 subtype, are deficient in autism spectrum disorder (ASD) …

Microglia, the resident macrophages in the central nervous system, are thought to be
maintained by a local self-renewal mechanism. Although preclinical and in vitro studies …

Abstract [11 C] raclopride is a well established PET tracer for the quantification of dopamine
2/3 receptors (D 2/3 R) in the striatum. Outside of the striatum the receptor density is up to …

Major depression is a significant contributor to the global burden of disease, and its
pathophysiology is largely unknown. The serotonin hypothesis is, however, the model with …

Background Reliable quantification of dopamine transporter (DAT), a biomarker for
Parkinson's disease (PD), is essential for diagnostic purposes as well as for evaluation of …